"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: A blood sample for CA 19-9 (cancer detection test).
- Who it may be relevant to
- Registry conditions: Pancreatic Ductal Adenocarcinoma (PDAC). Basic parameters: 50 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes. Purpose: To improve the rates of early detection of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.
Interventions
- Procedure A blood sample for CA 19-9 (cancer detection test)
* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline. * Contrast CT abdomen - Pancreas protocol will be done at baseline. * EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you. * If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done.
Primary outcome measures
- Incidence of PDAC at 3 years [Time frame: 3yrs]
Secondary outcome measures (1)
- • Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years [Time frame: baseline and 3yrs]
Eligibility criteria
Inclusion criteria
- Age > 50 years
- Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
- Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not > 125 mg/dl
- END-PDAC score > 2
Exclusion criteria
- Known or newly detected chronic pancreatitis
- Past history of pancreatic cancer
- History of steroid use
- Contraindications for EUS
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06044064 · PDAC-NOD-001